Bengaluru‑based CrisprBits closed a $3 million pre‑Series A round led by Spectrum Impact to commercialize its PathCrisp CRISPR diagnostics and advance a CRISPR strain‑engineering platform for industrial applications. The company plans to expand manufacturing capacity for rapid diagnostics spanning human, animal and food safety markets and to roll out PathCrisp tests internationally across Africa and Latin America. CrisprBits also announced plans to develop EdiCrisp and CurieCrisp platforms for strain engineering and preclinical therapeutics. The raise highlights continued funding interest in decentralized, rapid CRISPR diagnostics and regional biotech scale‑up in India.